Demographics and ITP characteristics at inclusion
| . | Total (n = 48)∗ . |
|---|---|
| Female, n (%) | 29 (60.5) |
| Age, median (IQR), y | 58.5 (41-73.5) |
| ITP previous treatment, n (%) | |
| Corticosteroids and/or IV immunoglobulin | 48 (100) |
| Splenectomy | 6 (13) |
| Rituximab | 22 (46) |
| Dapsone/danazol | 23 (48) |
| >2 therapeutic lines | 22 (47) |
| Previous treatment with another TPO-RA† | 14 (29) |
| ITP duration at TPO-RA initiation, n (%) | |
| Persistent | 18 (37) |
| Chronic | 30 (63) |
| ITP duration at inclusion (starting TPO-RA discontinuation) | |
| Persistent, n (%) | 2 (4) |
| Chronic, n (%) | 46 (96) |
| Median (IQR), y | 6 (2.8-10) |
| TPO-RA drug class at inclusion | |
| Romiplostim, n (%) | 8 (17) |
| Weekly dose, μg/kg × body weight, median (IQR), (n = 7) | 4 (3-6) |
| Eltrombopag, n (%) | 40 (83) |
| Daily dose, median (IQR), mg (n = 40) | 50 (25-50) |
| TPO-RA duration, median (IQR), y (n = 46) | 1.6 (1.0-3.8) |
| Maximal platelet count under TPO-RAs treatment, × 109/L (IQR) | 291 (215-408) |
| . | Total (n = 48)∗ . |
|---|---|
| Female, n (%) | 29 (60.5) |
| Age, median (IQR), y | 58.5 (41-73.5) |
| ITP previous treatment, n (%) | |
| Corticosteroids and/or IV immunoglobulin | 48 (100) |
| Splenectomy | 6 (13) |
| Rituximab | 22 (46) |
| Dapsone/danazol | 23 (48) |
| >2 therapeutic lines | 22 (47) |
| Previous treatment with another TPO-RA† | 14 (29) |
| ITP duration at TPO-RA initiation, n (%) | |
| Persistent | 18 (37) |
| Chronic | 30 (63) |
| ITP duration at inclusion (starting TPO-RA discontinuation) | |
| Persistent, n (%) | 2 (4) |
| Chronic, n (%) | 46 (96) |
| Median (IQR), y | 6 (2.8-10) |
| TPO-RA drug class at inclusion | |
| Romiplostim, n (%) | 8 (17) |
| Weekly dose, μg/kg × body weight, median (IQR), (n = 7) | 4 (3-6) |
| Eltrombopag, n (%) | 40 (83) |
| Daily dose, median (IQR), mg (n = 40) | 50 (25-50) |
| TPO-RA duration, median (IQR), y (n = 46) | 1.6 (1.0-3.8) |
| Maximal platelet count under TPO-RAs treatment, × 109/L (IQR) | 291 (215-408) |